Decreased ST2 expression is associated with gastric cancer progression and pathogenesis

  • Authors:
    • Feihu Bai
    • Fangyun Ba
    • Yanjie You
    • Yaning Feng
    • Wei Tao
    • Chuanxia Wu
    • Mengna Jiu
    • Yongzhan Nie
  • View Affiliations

  • Published online on: April 5, 2019     https://doi.org/10.3892/ol.2019.10223
  • Pages: 5761-5767
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is a type of cancer with increasing incidence and high mortality rates, but molecular biomarkers of diagnostic and therapeutic value are currently lacking. The aim of the present study was to examine the expression pattern of the interleukin 1 receptor‑like 1 (ST2) protein and assess its clinicopathological significance in gastric cancer. Western blot analysis of 12 gastric cancer specimens and paired adjacent tissues demonstrated that the protein levels of 2 isoforms of ST2, soluble secreted ST2 and the ST2 variant without the third immunoglobulin motif and splicing in the C‑terminal, were markedly decreased in cancer tissues compared with non‑cancerous tissues. Immunohistochemical analysis demonstrated that ST2 protein expression was markedly decreased in primary gastric cancer tissues (39.1%, 90/230) compared with adjacent non‑cancerous tissues (60.7%, 54/89) (P<0.05). Statistical analysis demonstrated that decreased ST2 expression was significantly associated with advanced tumor node metastasis stage (P<0.001) and tumor differentiation (P<0.001). These data suggest that ST2 protein may be a valuable biomarker of gastric cancer progression and pathogenesis.

References

1 

Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M and Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 36:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Bozzetti F, Yu W, Baratti D, Kusamura S and Deraco M: Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 98:273–276. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg. 87:236–242. 2000. View Article : Google Scholar : PubMed/NCBI

4 

Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, Katashima R, Itakura M and Tominaga S: Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 264:397–406. 1999. View Article : Google Scholar : PubMed/NCBI

5 

Bergers G, Reikerstorfer A, Braselmann S, Graninger P and Busslinger M: Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 13:1176–1188. 1994. View Article : Google Scholar : PubMed/NCBI

6 

Hayakawa H, Hayakawa M, Kume A and Tominaga S: Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 282:26369–26380. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Trajkovic V, Sweet MJ and Xu D: T1/ST2-an IL-1receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15:87–95. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Hentschke I, Graser A, Melichar VO, Kiefer A, Zimmermann T, Kroß B, Haag P, Xepapadaki P, Papadopoulos NG, Bogdan C and Finotto S: IL-33/ST2 immune responses to respiratory bacteria in pediatric asthma. Sci Rep 7:43426. 2017. View Article : Google Scholar

9 

Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K and Akira S: Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 301:640–643. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Siede J, Fröhlich A, Datsi A, Hegazy AN, Varga DV, Holecska V, Saito H, Nakae S and Löhning M: IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFβ release. PLoS One. 11:e01615072016. View Article : Google Scholar : PubMed/NCBI

11 

van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, Westenbrink BD, Brunner-la Rocca HP, van Miltenburg AJM, Boersma E, Hillege HL, Akkerhuis KM; TRIUMPH Investigators, ; et al: Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol. 70:2378–2388. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Ko FW, Yan BP, Lam YY, Chu JH, Chan KP and Hui DS: Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress. Respirology. 21:137–142. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Zhang JF, Wang P, Yan YJ, Li Y, Guan MW, Yu JJ and Wang XD: IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol Rep. 38:2033–2042. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, Jonjic S and Lukic ML: ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 41:1902–1912. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, Chen X, Qin C, Zhu Z, Wakefield MR and Nicholl MB: IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol. 34:232017. View Article : Google Scholar : PubMed/NCBI

16 

Yoshida K, Arai T, Yokota T, Komatsu N, Miura Y, Yanagisawa K, Tetsuka T and Tominaga S: Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies. Hybridoma. 14:419–427. 1995. View Article : Google Scholar : PubMed/NCBI

17 

You Y, Bai F, Ye Z, Zhang N, Yao L, Tang Y and Li X: Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis. Mol Med Rep. 17:6812–6818. 2018.PubMed/NCBI

18 

Lin C, Xin S, Qin X, Li H, Lin L and You Y: Zoledronic acid suppresses metastasis of esophageal squamous cell carcinoma cells through upregulating the tight junction protein occuludin. Cytotechnology. 68:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI

19 

You Y, Yang W, Qin X, Wang F, Li H, Lin C, Li W, Gu C, Zhang Y and Ran Y: ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell Oncol (Dordr). 38:205–214. 2015. View Article : Google Scholar : PubMed/NCBI

20 

You Y, Li H, Qin X, Ran Y and Wang F: Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis-a short report. Cell Oncol (Dordr). 39:89–95. 2016. View Article : Google Scholar : PubMed/NCBI

21 

You Y, Li H, Qin X, Zhang Y, Song W, Ran Y and Gao F: Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients-a short report. Cell Oncol (Dordr). 38:485–491. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, et al: The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology. 5:e10629662015. View Article : Google Scholar : PubMed/NCBI

23 

Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang L, Zhang Z, Zhang Y, et al: Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 198:1365–1375. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Haga Y, Yanagisawa K, Ohto-Ozaki H, Tominaga S, Masuzawa T and Iwahana H: The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur J Biochem. 270:163–170. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN and Lukic ML: Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 134:1669–1682. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and Hu WH: IL-33 promotes gastric cancer cell invasion and migration Via ST2-ERK1/2 pathway. Dig Dis Sci. 60:1265–1272. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Sun P, Ben Q, Tu S, Dong W, Qi X and Wu Y: Serun interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 56:3596–3601. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Schmieder A, Multhoff G and Radons J: Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 60:514–521. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Levescot A, Flamant S, Basbous S, Jacomet F, Féraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, et al: BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res. 74:2669–2676. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, Fang D, Zhang Y, Kuzel TM and Zhang B: Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 7:61069–61080. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O and Radeke HH: High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 6:311–318. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Bai, F., Ba, F., You, Y., Feng, Y., Tao, W., Wu, C. ... Nie, Y. (2019). Decreased ST2 expression is associated with gastric cancer progression and pathogenesis. Oncology Letters, 17, 5761-5767. https://doi.org/10.3892/ol.2019.10223
MLA
Bai, F., Ba, F., You, Y., Feng, Y., Tao, W., Wu, C., Jiu, M., Nie, Y."Decreased ST2 expression is associated with gastric cancer progression and pathogenesis". Oncology Letters 17.6 (2019): 5761-5767.
Chicago
Bai, F., Ba, F., You, Y., Feng, Y., Tao, W., Wu, C., Jiu, M., Nie, Y."Decreased ST2 expression is associated with gastric cancer progression and pathogenesis". Oncology Letters 17, no. 6 (2019): 5761-5767. https://doi.org/10.3892/ol.2019.10223